Company intelligence / Profile preview

Cadrenal Therapeutics

Ponte Vedra, Florida, United Statescadrenal.com ↗

Ownership: Public · CVKD
Employees: ~4
Development stage: Other

Overview

Tecarfarin has been evaluated in 11 human clinical trials in over 1,000 individuals. In Phase 1, Phase 2 and Phase 2/3 clinical trials, tecarfarin has generally been well-tolerated in healthy adults and patients with ESKD and chronic kidney disease (CKD). 269 patients were treated for at least 6 months and 129 patients were treated for one year or more. The FDA has provided guidance on the design of a future Phase 3 trial.

Therapeutic areas: HematologyCardiovascular
Modalities: Small molecules (oral anticoagulant)
Industry: Biotech

Drug pipeline

7 assets

tecarfarin

6 more assets in the full pipeline.

Partnerships

Abbott Global Enterprises Limited (collaboration for TECH-LVAD trial)

Financials

Market cap: $3.6M
Total revenue: $0
Enterprise value: $1.2M

Beyond the preview

Go deeper on Cadrenal Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cadrenal Therapeutics.